February 3, 2026 - ChartAlert®

SYNGENE – Q3 FY26 Earnings Call – 23-Jan-26

SYNGENE’s topline faces near-term headwinds from single-product concentration, but diversification efforts (BMS, Bayview, clinical trials) could stabilize revenue by FY27; margins hinge on CDMO utilization and cost discipline, with EBITDA recovery lagging revenue by 12–18 months. Cash flow remains resilient but vulnerable to CAPEX overruns or prolonged revenue drag.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Librela stabilizes by H2 FY27, with partial revenue recovery (50% of lost run-rate). CDMO utilization reaches 60–70% in Mangalore/Bayview, driven by 1–2 new large-molecule contracts. Research services grow 8–10%, supported by biotech funding. FY27 revenue flat to +2%, EBITDA margins 23–25%.
Trigger: Zoetis resolves product issues; Syngene secures $20–30M annual CDMO contracts.

LAURUSLABS – Q3 FY26 Earnings Call – 23-Jan-26

LAURUSLABS: ARV-led generics and CDMO drive 15–25% growth, but biotech drag limits upside. EBITDA margins (26–28%) hinge on utilization and FX gains; ROCE recovery (18.5%→20–22%) rests on asset turnover. Gross margin at 60% needs ARV/CDMO mix, with risk of 55% under price pressure.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: CDMO grows 20% YoY (FY27), ARV stabilizes at ₹2,600 crore, peptide/ADC revenues commence in FY28 (~₹200–300 crore).
Outcome: Revenue CAGR of 18–22% (FY26–28), EBITDA margins at 26–28%, ROCE improves to 20–22%. CAPEX absorption drives asset turnover to 1.1x by FY28; net debt/EBITDA at 1.0–1.2x.

GODREJCP – Q3 FY26 Earnings Call – 23-Jan-26

Godrej Consumer expects 6–9% revenue growth, led by laundry liquids, incense, and EDP, while soaps and HI remain cyclical. EPS may rise 12–16% with 22–24% EBITDA margins, hinging on oil and Africa FX. Gross margins face pressure, though HI volatility narrows.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Oil stable (±5%) + Indonesia/FY27 recovery + Spic/pet food gradual scale.

Topline: India volume 6–7%, GAUM 8–10% INR growth. Laundry liquids/incense sticks drive 30% of incremental revenue.
Bottomline: EBITDA margin 22–24%, EPS growth 12–14%. Structural cost savings (media, supply chain) persist.
Margins: Gross margin stable; HI volatility contained (100–110 index range).

ULTRACEMCO – Q3 FY26 Earnings Call – 24-Jan-26

Ultratech Cement’s revenue growth faces execution risks, capping upside at 6–7%. EBITDA/ton expansion to INR1,000–1,100 hinges on pricing power, but input inflation and legal overhangs threaten 18–19% margins. Base case: 20%+ margins by FY27; bear case: compression to 18–19%.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Infrastructure projects execute as planned, driving 9–10% demand growth; (2) South India pricing stabilizes with institutional demand, supporting INR6–8/ton price hikes.
Outcome: Revenue grows at 9–10%, EBITDA/ton reaches INR1,000–1,100 by FY27, and net debt/EBITDA improves to 0.8–0.9x. Clinker conversion and lead distance targets met, delivering INR100/ton cost savings. Bottomline: EPS grows 12–15% annually, in line with consensus.

KOTAKBANK – Q3 FY26 Earnings Call – 24-Jan-26

Kotak Bank’s Base case sees NIMs steady at 4.5–4.6% with credit costs normalizing to 50–60bps and ROE at 12–13%. Bear case risks compression to 4.3–4.4% and higher costs. Bull case offers expansion above 4.7%, stronger ROE, and EPS upside.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Retail CV delinquencies plateau (slippages <1.2%); (2) Term deposit repricing completes by Q1 FY27.
Outcome: Credit costs normalize to 50–60bps by FY27; NIM stabilizes at 4.5–4.6% with CRR benefits. Unsecured portfolio grows 15–20% YoY, lifting ROE to 12–13%. Cost-to-income ratio improves to 46–47% on automation. EPS growth: 6–9% YoY.